Effect of mandibular advancement device treatment on HIF-1?, EPO and VEGF in the myocardium of obstructive sleep apnea-hypopnea syndrome rabbits.

ABSTRACT: The aim of this study was to investigate the effects of mandibular advancement device (MAD) therapy for obstructive sleep apnea-hypopnea syndrome (OSAHS) on hypoxia-inducible factor-1? (HIF-1?), erythropoietin (EPO) and vascular endothelial growth factor (VEGF) in myocardial tissue. New Zealand rabbits were used to develop OSAHS and MAD models. Cone beam computed tomography (CBCT) of the upper airway and polysomnography (PSG) recordings were performed with the animals in the supine position. All of the animals were induced to sleep in a supine position for 4-6 h each day and were observed continuously for 8 weeks. The myocardial tissue of the three groups was dissected to measure the expression of HIF-1?, EPO and VEGF. The results showed that there was higher expression of HIF-1?, EPO and VEGF in the OSAHS group than those in the MAD and control groups. MAD treatment significantly downregulated the expression of HIF-1?, EPO and VEGF in the OSAHS animals. We concluded that MAD treatment could significantly downregulate the increased expression of HIF-1?, EPO and VEGF in OSAHS rabbits, improving their myocardial function.

SUBMITTER: Zhu D 

PROVIDER: S-EPMC7414037 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature